Role of the cholinesterase inhibitors in the treatment of schizophrenia

Bibliography

• Money TT, Scarr E, Udawela M, Treating schizophrenia: novel targets for the cholinergic system. CNS Neurol Disord Drug Targets 2010;9:241-56
   PubMed Web of Science ®Google Scholar
• Wallace TL, Ballard TM, Pouzet B, Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav 2011;99:130-45
   PubMed Web of Science ®Google Scholar
• Picciotto MR, Alreja M, Jentsch JD. Chapter 1. Acetylcholine. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors, Neuropsychopharmacology: the fifth generation of progress. Lippincott, Williams, & Wilkins, Philadelphia, Pennsylvania; 2002
   Google Scholar
• Leonard S, Gault J, Adams C, Nicotinic receptors, smoking and schizophrenia. Restor Neurol Neurosci 1998;12:195-201
   PubMed Web of Science ®Google Scholar
• Radek RJ, Kohlhaas KL, Rueter LE, Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr Pharm Des 2010;16:309-22
   PubMed Web of Science ®Google Scholar
• Shekhar A, Potter WZ, Lightfoot J, Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008;165:1033-9
   PubMed Web of Science ®Google Scholar
• Martin LF, Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol 2007;78:225-46
   PubMed Web of Science ®Google Scholar
• Martin LF, Leonard S, Hall MH, Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am J Med Genet B Neuropsychiatr Genet 2007;144B:611-14
   PubMed Web of Science ®Google Scholar
• Olincy A, Harris JG, Johnson LL, Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006;63:630-8
   PubMed Web of Science ®Google Scholar
• Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 2006;184:523-39
   PubMed Web of Science ®Google Scholar
• Ryan RE, Loiacono RE. Nicotinic receptor subunit mRNA in the thalamus of the rat: relevance to schizophrenia? Neuroreport 2000;11:3693-8
   PubMed Web of Science ®Google Scholar
• Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 2006;27:482-91
   PubMed Web of Science ®Google Scholar
• Holt DJ, Herman MM, Hyde TM, Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 1999;94:21-31
   PubMed Web of Science ®Google Scholar
• Davidson M, Keefe RS. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr Res 1995;17:123-9
   PubMed Web of Science ®Google Scholar
• Berman JA, Talmage DA, Role LW. Cholinergic circuits and signaling in the pathophysiology of schizophrenia. Int Rev Neurobiol 2007;78:193-223
   PubMed Web of Science ®Google Scholar
• Scarr E, Dean B. Role of the cholinergic system in the pathology and treatment of schizophrenia. Expert Rev Neurother 2009;9:73-86
   PubMed Web of Science ®Google Scholar
• Brunzell DH, McIntosh JM. Alpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia. Neuropsychopharmacology 2012;37:1134-43
   PubMed Web of Science ®Google Scholar
• Powchik P, Davidson M, Haroutunian V, Postmortem studies in schizophrenia. Schizophr Bull 1998;24:325-41
   PubMed Web of Science ®Google Scholar
• Rees TM, Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs Today (Barc) 2003;39:75-83
   PubMed Web of Science ®Google Scholar
• Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;157:4-15
   PubMed Web of Science ®Google Scholar
• Ribeiz SR, Bassitt DP, Arrais JA, Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs 2010;24:303-17
   PubMed Web of Science ®Google Scholar
• Ichikawa J, Li Z, Dai J, Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002;956:349-57
   PubMed Web of Science ®Google Scholar
• Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev 2012;1:CD007967
   PubMedGoogle Scholar
• Lindenmayer JP, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res 2011;125:267-77
   PubMed Web of Science ®Google Scholar
• Keefe RS, Malhotra AK, Meltzer HY, Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008;33:1217-28
   PubMed Web of Science ®Google Scholar
• Stryjer R, Ophir D, Bar F, Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol 2012;35:161-4
   PubMed Web of Science ®Google Scholar
• Rao NP, Palaniyappan P, Chandur J, Successful use of donepezil in treatment of cognitive impairment caused by maintenance electroconvulsive therapy: a case report. J ECT 2009;25:216-18
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Conley RR, Dickinson D, Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008;165:82-9
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Davis M, Goff D, A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005;31:5-19
   PubMed Web of Science ®Google Scholar
• Keefe RS, Buchanan RW, Marder SR, Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull 2011; In press
   Web of Science ®Google Scholar
• Risch SC. Do cholinesterase inhibitors enhance cognition in schizophrenia? Curr Psychiatry 2008;7:96-100
   Google Scholar
• D'Souza DC, Esterlis I, Carbuto M, Lower ss2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry 2012;169:326-34
   PubMed Web of Science ®Google Scholar
• Niitsu T, Iyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr Pharm Des 2012;18:875-83
   PubMed Web of Science ®Google Scholar
• Goff DC, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav 2011;99:245-53
   PubMed Web of Science ®Google Scholar